As of November 9, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Ernexa Therapeutics Inc. The largest reported stake is Charles Cherington's, at 34.7%. 11 filings are on record since August 18, 2025 (Schedule 13D/A, February 17, 2026).
Sell to companies like Ernexa Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Freebird Partners LP · Sole voting: 0 · Shared voting: 119,015 · Sole dispositive: 0 · Shared dispositive: 119,015 · SCHEDULE 13G/A, 2026-10-30
- · Holder: Clear Street LLC · Percent: 0% · SCHEDULE 13G/A
- · Holder: John D. Halpern · Percent: 5.6% · SCHEDULE 13G/A
- · Holder: Freebird Partners LP · Percent: 9.9% · SCHEDULE 13G/A
- · Holder: Bleichroeder LP · Percent: 6.86% · SCHEDULE 13G
Ernexa Therapeutics Inc. has 11 Schedule 13D or 13G filings on record since 2025-08-18. 5 holders' latest filing reports 5% or more of common stock, par value $0.005 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 34.7% | 10,791,335 | SCHEDULE 13D/A, 2026-02-17 | 2026-02-10 | |
| 9.7% | 118,342 | SCHEDULE 13G/A, 2026-05-13 | 2026-02-10 | |
| Freebird Partners LP | 7% | 119,015 | SCHEDULE 13G/A, 2026-10-30 | 2026-08-05 |
| Bleichroeder LP | 6.86% | 80,000 | SCHEDULE 13G, 2026-05-14 | 2026-03-31 |
| 5.6% | 66,751 | SCHEDULE 13G/A, 2026-05-15 | 2026-02-10 | |
| Iaf, LLC | 4.1% | 315,779 | SCHEDULE 13G/A, 2025-08-18 | 2025-07-28 |
| Clear Street LLC | 0% | 0 | SCHEDULE 13G/A, 2026-05-20 | 2026-05-05 |
Holding shares or following this stake? See who's behind Ernexa Therapeutics Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Ernexa Therapeutics Inc. and the records around it.
Ernexa Therapeutics Inc. elsewhere on the record
- Form D filing Apr 2025
- Who owns it
Companies that share a holder
- Bleichroeder LP also filed stake reports on 16 other companies: MDxHealth SA (Oct 2026), Identiv, Inc. (INVE) (Aug 2026), Cellectar Biosciences, Inc. (Aug 2026)
- Clear Street LLC also filed stake reports on 16 other companies: Integrated Wellness Acquisition Corp (Aug 2026), StoneBridge Acquisition II Corporation (Aug 2026), ConnectM Technology Solutions, Inc. (May 2026)
Watch Ernexa Therapeutics Inc.
Get an email when Ernexa Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Ernexa Therapeutics Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Ernexa Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ernexa Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Freebird Partners LP | 0 | 119,015 | 0 | 119,015 | SCHEDULE 13G/A, 2026-10-30 |
| Freebird Investments LLC | 0 | 119,015 | 0 | 119,015 | SCHEDULE 13G/A, 2026-10-30 |
| Curtis Huff | 0 | 119,015 | 0 | 119,015 | SCHEDULE 13G/A, 2026-10-30 |
The latest filing identifies Ernexa Therapeutics Inc. by CUSIP 114082407 and gives its principal executive office as 1035 Cambridge Street, Suite 18A, Cambridge, MA 02141 (SCHEDULE 13G/A, 2026-10-30).
Purpose of Transaction (Item 4)
Charles Cherington
Item 4 is hereby amended by adding the following: The Reporting Person acquired 4,000,000 shares of the Issuer's Common Stock and 4,000,000 Warrants in the Offering. The Reporting Person has no present plan or proposal that relates to, or could result in, any of the events referred to in paragraphs (a) through (j) inclusive, of Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2026-02-17
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-18 | Iaf, LLC | 4.1% | SCHEDULE 13G/A |
| 2025-12-16 | Shameek Konar | 7.12% | SCHEDULE 13G/A |
| 2025-12-19 | Freebird Partners LP | 9.9% | SCHEDULE 13G/A |
| 2026-02-17 | Charles Cherington | 34.7% | SCHEDULE 13D/A |
| 2026-05-13 | Shameek Konar | 9.7% | SCHEDULE 13G/A |
| 2026-05-14 | Bleichroeder LP | 6.86% | SCHEDULE 13G |
| 2026-05-14 | Clear Street LLC | 12.8% | SCHEDULE 13G |
| 2026-05-15 | John D. Halpern | 5.6% | SCHEDULE 13G/A |
| 2026-05-15 | Freebird Partners LP | 9.9% | SCHEDULE 13G/A |
| 2026-05-20 | Clear Street LLC | 0% | SCHEDULE 13G/A |
| 2026-10-30 | Freebird Partners LP | 7% | SCHEDULE 13G/A |
Questions about who owns Ernexa Therapeutics Inc.
Who owns Ernexa Therapeutics Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Ernexa Therapeutics Inc.: Charles Cherington (34.7%, Schedule 13D/A, filed 2026-02-17), Shameek Konar (9.7%, Schedule 13G/A, filed 2026-05-13), Freebird Partners LP (7%, Schedule 13G/A, filed 2026-10-30), Bleichroeder LP (6.86%, Schedule 13G, filed 2026-05-14) and John D. Halpern (5.6%, Schedule 13G/A, filed 2026-05-15).
Who are the largest shareholders of Ernexa Therapeutics Inc.?
By the share each holder's latest filing reports, the largest holders of Ernexa Therapeutics Inc. on this page are Charles Cherington (34.7%), Shameek Konar (9.7%) and Freebird Partners LP (7%).
When did Charles Cherington buy into Ernexa Therapeutics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Charles Cherington on this page is the Schedule 13D/A, filed 2026-02-17, reporting 34.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Ernexa Therapeutics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 16, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| June 26, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| April 11, 2025 | Form D, private offering | $7.25M sold | Form D page | Source |
| November 14, 2024 | Form D, private offering | $3.89M sold | Form D page | Source |
| November 14, 2024 | Form D, private offering | $1.14M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Ernexa Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.